THIORIDAZINE HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Chartwell Rx	THIORIDAZINE HYDROCHLORIDE	thioridazine hydrochloride	TABLET;ORAL	088131	ANDA	Chartwell RX, LLC	62135-934-90	90 TABLET, FILM COATED in 1 BOTTLE (62135-934-90)	1983-08-30
Chartwell Rx	THIORIDAZINE HYDROCHLORIDE	thioridazine hydrochloride	TABLET;ORAL	088133	ANDA	Chartwell RX, LLC	62135-936-90	90 TABLET, FILM COATED in 1 BOTTLE (62135-936-90)	1983-08-30
Chartwell Rx	THIORIDAZINE HYDROCHLORIDE	thioridazine hydrochloride	TABLET;ORAL	088134	ANDA	Chartwell RX, LLC	62135-938-90	90 TABLET, FILM COATED in 1 BOTTLE (62135-938-90)	1983-08-30
Chartwell Rx	THIORIDAZINE HYDROCHLORIDE	thioridazine hydrochloride	TABLET;ORAL	088135	ANDA	Chartwell RX, LLC	62135-939-90	90 TABLET, FILM COATED in 1 BOTTLE (62135-939-90)	1984-11-20
Mylan	THIORIDAZINE HYDROCHLORIDE	thioridazine hydrochloride	TABLET;ORAL	088004	ANDA	Mylan Pharmaceuticals Inc.	0378-0612-01	100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0378-0612-01)	1983-03-15
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report details the current landscape of suppliers for Thioridazine Hydrochloride active pharmaceutical ingredient (API). It identifies key manufacturers, their manufacturing capacities, regulatory compliance, and potential supply chain risks for companies requiring this compound. The analysis focuses on established and emerging players, highlighting geographical distribution and quality control measures relevant to pharmaceutical production.

WHO ARE THE PRIMARY MANUFACTURERS OF THIORIDAZINE HYDROCHLORIDE API?

The production of Thioridazine Hydrochloride API is concentrated among a limited number of global manufacturers, primarily located in India and China. These entities possess the specialized chemical synthesis capabilities and regulatory certifications required for pharmaceutical-grade API production.

Key Manufacturers Identified:

Abbott Laboratories (formerly through various acquired entities): While Abbott Laboratories is a significant pharmaceutical company, direct API manufacturing of Thioridazine Hydrochloride may be outsourced or handled by specific divisions. Historical involvement indicates a strong market presence.
Teva Pharmaceutical Industries Ltd.: As a major global generic pharmaceutical manufacturer, Teva has historically been involved in the production or sourcing of Thioridazine Hydrochloride. Their extensive supply chain network is a notable factor.
Wockhardt Ltd.: An Indian pharmaceutical and biotechnology company, Wockhardt is known for its API manufacturing capabilities across various therapeutic areas. Their facilities are typically compliant with international standards.
Divi’s Laboratories Limited: Another prominent Indian API manufacturer, Divi’s Laboratories has a broad portfolio and a reputation for large-scale production of complex APIs.
Zhejiang NHU Co., Ltd.: Based in China, NHU is a significant player in the global API market, producing a wide range of pharmaceutical ingredients. Their scale and cost-effectiveness are competitive advantages.
Jiangsu Yangzijiang Pharmaceutical Group Ltd.: This Chinese pharmaceutical company is involved in both finished dosage forms and API production, with a substantial domestic and international reach.

The market share distribution among these manufacturers can fluctuate based on production volumes, regulatory approvals, and long-term supply agreements. Specific volume data is proprietary but can be inferred from market intelligence reports and industry trade associations.

WHAT ARE THE CURRENT MANUFACTURING CAPACITIES AND TECHNOLOGIES EMPLOYED?

Manufacturing capacities for Thioridazine Hydrochloride API vary significantly between producers. Large-scale manufacturers in India and China leverage multi-purpose chemical synthesis plants capable of producing metric tons of API annually. These facilities typically employ standard chemical reaction pathways, including alkylation and condensation reactions, to synthesize the phenothiazine core structure and attach the side chains characteristic of Thioridazine.

Typical Manufacturing Process Steps:

Phenothiazine Synthesis: Formation of the core phenothiazine ring system.
Side Chain Alkylation: Attachment of the piperidine and N-methylpiperidine side chains to the phenothiazine nitrogen atom.
Salt Formation: Conversion of the free base to the hydrochloride salt for improved stability and solubility.
Purification: Crystallization and chromatography to achieve pharmaceutical-grade purity.
Drying and Milling: Final processing to obtain the desired particle size and physical form.

Technological Considerations:

Batch Processing: The majority of API manufacturing for complex molecules like Thioridazine Hydrochloride is conducted using batch processing. This allows for precise control over reaction conditions and product quality at each stage.
Process Optimization: Manufacturers continuously seek to optimize synthesis routes to improve yield, reduce by-product formation, and lower manufacturing costs. This can involve exploring new catalysts, solvent systems, and reaction parameters.
Quality Control Instrumentation: Advanced analytical instrumentation, including High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR), is critical for ensuring API purity, potency, and identification.

Capacity figures are often not publicly disclosed but are estimated based on the size and number of production lines, historical output, and known market supply. Companies with dedicated facilities or significant investment in process chemistry are likely to have higher capacities.

WHAT ARE THE REGULATORY COMPLIANCE AND QUALITY CONTROL STANDARDS FOR THIORIDAZINE HYDROCHLORIDE API?

Manufacturers supplying Thioridazine Hydrochloride API to regulated markets must adhere to stringent international quality and regulatory standards. This ensures the safety, efficacy, and consistency of the API.

Key Regulatory Requirements and Standards:

Current Good Manufacturing Practices (cGMP): Compliance with cGMP guidelines, as established by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, is mandatory. This covers all aspects of manufacturing, from raw material sourcing to finished API release.
Drug Master Files (DMFs): Manufacturers typically file DMFs with regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows regulatory bodies to review the API manufacturing process without disclosing proprietary information to the drug product manufacturer.
Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs): For APIs intended for the European market, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) demonstrates compliance with European Pharmacopoeia (Ph. Eur.) monographs.
Pharmacopoeial Standards: The API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs define identity, purity, strength, and quality requirements.
Impurity Profiling: Detailed analysis and control of impurities, including process-related impurities, degradation products, and residual solvents, are critical. Limits for specific impurities are set by regulatory guidelines (e.g., ICH Q3A/B).
Stability Testing: Manufacturers must conduct comprehensive stability studies to determine the shelf-life of the API under various storage conditions.

Auditing and Inspections:

Pharmaceutical companies that source Thioridazine Hydrochloride API typically conduct rigorous audits of their suppliers' manufacturing facilities to verify cGMP compliance. Regulatory agencies also conduct periodic inspections of API manufacturing sites. Non-compliance can lead to import alerts, product recalls, and significant disruptions to the supply chain.

WHAT ARE THE KEY GEOGRAPHICAL LOCATIONS OF API MANUFACTURERS AND IMPORTERS?

The geographical distribution of Thioridazine Hydrochloride API manufacturing is predominantly concentrated in Asia, with India and China being the leading production hubs. This concentration is driven by factors including lower manufacturing costs, a skilled chemical workforce, and established pharmaceutical infrastructure.

Major Manufacturing Regions:

India: Numerous API manufacturers in India produce Thioridazine Hydrochloride. States like Gujarat and Maharashtra are significant centers for chemical and pharmaceutical production. Indian manufacturers are well-established in supplying global markets and possess a strong track record with international regulatory bodies.
China: Chinese API manufacturers also represent a substantial portion of the global supply. Provinces such as Jiangsu, Zhejiang, and Shandong are key manufacturing areas. China’s role as a global chemical manufacturing powerhouse extends to its pharmaceutical API sector.

Key Importing Regions/Countries:

Pharmaceutical companies that formulate finished dosage forms of Thioridazine Hydrochloride import API from these manufacturing regions. The primary importing regions include:

North America (United States, Canada): These markets have significant demand for psychiatric medications, including those containing Thioridazine Hydrochloride.
Europe: Countries within the European Union and the UK are major importers, requiring adherence to EMA and MHRA regulations.
Asia: While also a manufacturing hub, certain Asian countries may import API for local formulation or if specific local manufacturers have specialized capabilities.
Other Regions: Latin America, Africa, and Oceania also represent markets for imported Thioridazine Hydrochloride API.

The global supply chain is thus characterized by a flow of API from manufacturing centers in Asia to formulation sites worldwide. Logistics, customs, and international trade regulations play a crucial role in the efficient movement of this API.

WHAT ARE THE POTENTIAL SUPPLY CHAIN RISKS AND MITIGATION STRATrEGIES?

The supply chain for Thioridazine Hydrochloride API is subject to various risks that can impact availability, cost, and quality. Proactive identification and mitigation of these risks are essential for pharmaceutical companies.

Key Supply Chain Risks:

Single-Source Dependency: Relying on a single manufacturer for API can create significant vulnerability. If that supplier experiences production issues, regulatory sanctions, or goes out of business, supply can be severely disrupted.
Geopolitical Instability and Trade Disputes: Political events, trade wars, or changes in trade policies in major manufacturing countries (India, China) can lead to import/export restrictions, tariffs, or supply interruptions.
Regulatory Changes and Enforcement: Stricter enforcement of environmental regulations or changes in cGMP requirements can force manufacturers to halt production or invest heavily in compliance, potentially impacting supply and cost.
Quality Control Failures: A single batch failure due to contamination, incorrect potency, or presence of unacceptable impurities can lead to product recalls, regulatory actions, and significant reputational damage for both the API manufacturer and the drug product company.
Raw Material Sourcing Issues: The synthesis of Thioridazine Hydrochloride relies on various chemical intermediates and raw materials. Disruptions in the upstream supply chain for these precursors can affect API production.
Natural Disasters and Pandemics: Events like earthquakes, floods, or global health crises can disrupt manufacturing operations, logistics, and personnel availability in key production regions.
Intellectual Property and Patent Issues: While Thioridazine itself is an older drug and its composition of matter patent has long expired, any novel synthesis routes or purification methods developed by manufacturers could be subject to IP protection, potentially limiting access.

Mitigation Strategies:

Dual or Multi-Sourcing: Identify and qualify at least two, preferably three, independent suppliers for Thioridazine Hydrochloride API. This diversifies the supply base and reduces reliance on any single entity.
Supplier Audits and Qualification Programs: Conduct thorough, regular audits of all potential and existing suppliers. This includes assessing their cGMP compliance, quality management systems, financial stability, and business continuity plans.
Inventory Management and Buffer Stocks: Maintain adequate safety stock of API at formulation sites to cover short-term supply disruptions. The level of buffer stock should be determined by lead times, supplier reliability, and criticality of the drug.
Supply Chain Mapping and Transparency: Understand the entire supply chain, including key raw material suppliers. This provides visibility into potential upstream vulnerabilities.
Contractual Agreements: Establish robust supply agreements with clear terms regarding quality, delivery schedules, pricing, force majeure clauses, and change control procedures.
Regulatory Intelligence Monitoring: Actively monitor regulatory developments in key manufacturing and importing countries to anticipate potential compliance challenges or trade policy shifts.
Geographical Diversification: If feasible, qualify suppliers in different geographical regions to mitigate risks associated with localized events.
Long-Term Partnerships: Develop strong, collaborative relationships with key suppliers. This fosters better communication, problem-solving, and commitment.

A comprehensive risk assessment and a well-defined mitigation plan are critical for ensuring a resilient and secure supply of Thioridazine Hydrochloride API for the production of essential medicines.

WHAT IS THE MARKET TREND AND FUTURE OUTLOOK FOR THIORIDAZINE HYDROCHLORIDE API?

The market for Thioridazine Hydrochloride API is largely driven by its established use in the treatment of certain psychiatric disorders, primarily schizophrenia and psychosis. As an older, generic medication, its market dynamics differ from those of newer, patented drugs.

Market Trends:

Stable but Mature Demand: Demand for Thioridazine Hydrochloride is generally stable, reflecting its long-standing therapeutic role. However, the introduction of newer antipsychotic medications with potentially better efficacy and side-effect profiles has led to a gradual shift away from older agents like Thioridazine in some markets.
Price Sensitivity: Given its generic status, price is a significant factor in the market for Thioridazine Hydrochloride API. Manufacturers compete on cost-effectiveness, making efficient production and supply chain management crucial.
Regulatory Scrutiny: While the drug has a long history, ongoing regulatory expectations regarding impurity control (e.g., genotoxic impurities) and consistent quality mean that manufacturers must maintain high standards.
Generic Competition: The market is characterized by intense competition among generic manufacturers. This puts pressure on API suppliers to offer competitive pricing and reliable supply.
Therapeutic Niche: Thioridazine Hydrochloride may retain its position in specific therapeutic niches or in regions where newer treatments are less accessible or affordable.

Future Outlook:

The future outlook for Thioridazine Hydrochloride API is characterized by moderate growth, driven primarily by demand in emerging markets and its continued use in established indications. However, several factors will shape its trajectory:

Competition from Newer Antipsychotics: The ongoing development and adoption of atypical antipsychotics with improved safety and tolerability profiles will likely continue to moderate the growth of Thioridazine Hydrochloride in developed markets.
Cost-Effectiveness in Emerging Markets: In regions with healthcare budget constraints, Thioridazine Hydrochloride’s affordability will likely sustain its demand. The generic nature of the API makes it a cost-effective option for widespread use.
Regulatory Landscape: Evolving regulatory requirements for API quality and manufacturing standards will necessitate continuous investment in compliance for manufacturers. Companies that can consistently meet these standards will maintain their market position.
Supply Chain Resilience: As pharmaceutical supply chains face increasing scrutiny, companies that can demonstrate robust, diversified, and compliant API sourcing will be at an advantage. The focus on supply chain security will persist.
Potential for Niche Applications: While its primary use is well-established, ongoing research could theoretically identify new, albeit likely limited, therapeutic applications or formulations that might influence future demand.

Overall, the Thioridazine Hydrochloride API market is expected to remain a stable, albeit mature, segment of the pharmaceutical industry. Success will hinge on cost-competitiveness, stringent quality adherence, and effective supply chain management.

KEY TAKEAWAYS

Thioridazine Hydrochloride API manufacturing is dominated by Indian and Chinese suppliers, with key players including Wockhardt, Divi’s Laboratories, and Zhejiang NHU Co., Ltd.
Manufacturers operate under strict cGMP guidelines and must file DMFs with regulatory agencies like the FDA and EMA.
The primary risks to the supply chain include single-source dependency, geopolitical instability, and quality control failures, which can be mitigated through dual-sourcing and robust supplier qualification programs.
The market is mature, with stable demand driven by its use as a generic antipsychotic, particularly in cost-sensitive emerging markets, facing competition from newer therapeutic agents.

FREQUENTLY ASKED QUESTIONS

What is the primary therapeutic use of Thioridazine Hydrochloride? Thioridazine Hydrochloride is primarily used to treat schizophrenia and psychosis.
Are there any major patent expiries that impact Thioridazine Hydrochloride API production? The composition of matter patent for Thioridazine expired long ago, allowing for generic manufacturing. However, novel synthesis or purification methods could be subject to intellectual property protection.
What are the most common impurities found in Thioridazine Hydrochloride API, and how are they controlled? Common impurities can include related substances from synthesis by-products, degradation products, and residual solvents. Manufacturers control these through optimized synthesis routes, rigorous purification steps, and validated analytical testing according to pharmacopoeial monographs and ICH guidelines.
How does the regulatory status of API suppliers in India and China compare for Western markets? Major API suppliers in India and China are regularly inspected by Western regulatory bodies such as the FDA and EMA. Compliance with cGMP and successful inspection outcomes are critical for market access. The regulatory oversight is substantial for both regions.
What impact does the environmental regulatory landscape have on Thioridazine Hydrochloride API production in key manufacturing regions? Increasingly stringent environmental regulations in both India and China require manufacturers to invest in waste treatment and pollution control measures. This can affect production costs and, in some cases, lead to temporary shutdowns or capacity reductions if compliance is not met.

Suppliers and packagers for generic pharmaceutical drug: THIORIDAZINE HYDROCHLORIDE